New epilepsy drug dp-vpa jointly developed by Enhua pharmaceutical and d-pharm in Israel has entered the phase III clinical trial

Jiangsu Enhua Pharmaceutical Co., Ltd said in the morning of February 14 that the dp-vpa innovative drug jointly developed by Enhua pharmaceutical and Israeli d-pharm company is currently in the phase III clinical trial stage The company issued a notice on May 30, 2011, saying that the company and Israeli d-pharm company had a discussion on the exclusive license and cooperative development of dp-vpa in China, and signed the license and joint development agreement Dp-vpa is a new drug developed by dp-vpa for the treatment of epilepsy, migraine and bi-directional affective disorder Dp-vpa, as a prodrug of valproic acid, has good targeting ability and can release the active components in the focus accurately Compared with valproic acid, dp-vpa showed better safety and pharmacokinetics in preclinical and clinical studies Valproic acid is the first-line drug for epilepsy treatment in China Although it has good efficacy, a series of adverse reactions limit the maximum dosage and wide use of valproic acid Dp-vpa is expected to be a safer and more efficient alternative to valproate D-pharm is an Israeli technology development biopharmaceutical company, Founded in 1993, it is one of the most famous pharmaceutical R & D companies in Israel It is mainly engaged in the research and development of innovative patented drugs for the treatment of central nervous system diseases and cancer The company has developed a series of new products using its innovative platform technology, including anti stroke, anti epilepsy, anti migraine products in the later stage of R & D, and some treatment of neurodegeneration A preclinical research project in the field of diseases D-pharm was listed on the Tel Aviv Stock Exchange in August 2009 under the stock code of DPRM Jiangsu Enhua Pharmaceutical Co., Ltd as the leader of nervous system drugs in China, its R & D ability is second to none and its product reserves are rich The main businesses are anesthetics and psychoactive drugs, which are the main sources of profits The products of anesthetics mainly include propofol injection, remifentanil, dextromethomidine hydrochloride injection, etc., and the products of psychoactive drugs mainly include yidiprolen oxalate tablets, aripiprazole tablets, etc